Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Infectious Disease
•
Transplant Infectious Disease
Is there a role for secondary CMV prophylaxis in solid organ transplant patients?
Related Questions
Do you use letermovir as CMV prophylaxis in solid organ transplant patients?
Do you recommend screening patients in high endemic regions for coccidioidomycosis prior to initiation of anti-TNF inhibitor therapy?
What is your approach to vaccinations and titers for patients with myeloma, who are immunosuppressed and do not have appropriate antibody responses to vaccines?
Is there ever a role for the use of CMV immune globulin for treatment of CMV viremia and/or disease?
How long do you treat uncomplicated gram-negative rod bacteremia in solid organ transplant recipients?
What is current best practice with regards to antibacterial prophylaxis in patients with hematologic malignancy and resolved neutropenic fever (>72 hours)?
When is drug-level monitoring helpful in the treatment of pan-susceptible tuberculosis on a standard four-drug therapy regimen?
How do you approach management of patients with active RA and recurrent non-severe C.diff?
If a patient does not tolerate completion of a course of LTBI treatment with either 6-9INH or 3HP, is it reasonable to complete a subsequent partial course of rifampin alone, or does the rifampin treatment course need to be re-started?
What is your approach to recurrent asymptomatic bacteriuria in pregnancy for patients without personal history of recurrent UTIs or pyelonephritis?
